Heart Tronics Inc (HRTT)

[TechKim]

Signalife Hires Director of Sales
Thursday June 28, 9:15 am ET


GREENVILLE, S.C., June 28 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) -- Signalife, Inc. announced that it has hired Elizabeth Peacock as its Global Director of Sales. Ms. Peacock has a broad knowledge of the healthcare space with a focus on cardiovascular medical devices. Throughout her career she has gained experience in sales and marketing leadership as well as business strategy. She speaks four foreign languages (French, Italian, German, and Spanish) which allow her to take advantage of opportunities in international markets as we gain the required approvals to sell in those countries.


She received her BA degree in England from Bath University in business and languages where she graduated Magna Cum Laude. In addition she earned an MA from Reading University where she again graduated with honors, Magna Cum Laude.

Upon graduation, she began her career with Johnson and Johnson's Ortho Division in The Middle East and Africa. She then came to the US and was employed by Intermedics, Inc. with implantable cardiovascular products and infusion pumps.

She joined Research Medical and acted as Director of Sales for seven years and was able to drive sales increases of over 20% year over year culminating in Research Medical's acquisition by Baxter. Ms. Peacock was actively involved in the acquisition negotiations and transition strategies. She was retained by Baxter's Intercontinental Division and received a promotion to head up business strategies for the cardiovascular products group. She also participated in the preparation to spin off Baxter's CardioVascular Group to form Edwards Lifesciences.

Since leaving Baxter, Ms. Peacock has been involved with two start up companies, firstly as Vice President of Sales and Marketing for Hancock Jaffe Laboratories, a developer of cardiovascular and vascular tissue grafts, and most recently as Vice President of Sales & Marketing for Ameritox, a specialty diagnostics company.

"We are excited to welcome Liz to our team as we focus efforts on revenue generation. She has a tremendous history of success creating sales results and we look forward to her success driving revenues for Signalife, stated Pam Bunes, CEO of Signalife, Inc.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance for heart monitoring and other biomedical devices incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical devices incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Signalife, Inc.